Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection.

[Guest guest]

Hepatology. 2010 Dec 6. [Epub ahead of print]

Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver

transplantation for hepatitis C infection.

Berres ML, Trautwein C, Schmeding M, Eurich D, Tacke F, Bahra M, Neuhaus P,

Neumann UP, Wasmuth HE.

Medical Department III, University Hospital Aachen, Aachen, Germany.

Abstract

The recurrence of liver fibrosis after liver transplantation (LT) for hepatitis

C virus (HCV) infection is responsible for graft loss and patient mortality.

Although the contribution of the immune system to fibrosis recurrence is

anticipated, systematic studies evaluating immune parameters as predictive

markers of allograft fibrosis are lacking. The infiltration of immune cells into

the graft is governed by chemokines. Here we assessed the predictive value of

serum levels of chemokines [chemokine (C-X-C motif) ligand 9 (CXCL9), CXCL10,

CXCL11, and chemokine (C-C motif) ligand 2 (CCL2)] with respect to fibrosis

recurrence after LT in 90 HCV-infected organ recipients. Chemokines were

determined within the first and third years after LT and were correlated with

histological fibrosis progression in protocol biopsy samples at 1, 3, 5, and 7

years (median follow-up = 3 years). The association of chemokines with fibrosis

progression was assessed by univariate and multivariate analyses and by

regression analysis. The results for the analyzed chemokines showed that CXCL10

levels in the first year after LT were strongly associated with early fibrosis

recurrence (P = 0.005) independently of risk confounders (including the donor

age, HCV viral load, HCV genotype, acute rejection, and inflammatory activity).

As assessed by regression analysis, a CXCL10 serum level ˜ 140 pg/mL was

significantly predictive of the absence of F2 fibrosis (P = 0.001), whereas a

level ˜ 220 pg/mL early after LT predicted the absence of F3 fibrosis during

follow-up (P = 0.035). Conclusion: CXCL10 is an independent biomarker of the

recurrence of significant fibrosis after LT for HCV infection. These results

might guide patients' care after transplantation and help us to select optimal

candidates for antiviral therapy post-LT. (HEPATOLOGY 2011;).

PMID: 21225643 [PubMed - as supplied by publisher]

[Guest guest]

Hepatology. 2010 Dec 6. [Epub ahead of print]

Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver

transplantation for hepatitis C infection.

Berres ML, Trautwein C, Schmeding M, Eurich D, Tacke F, Bahra M, Neuhaus P,

Neumann UP, Wasmuth HE.

Medical Department III, University Hospital Aachen, Aachen, Germany.

Abstract

The recurrence of liver fibrosis after liver transplantation (LT) for hepatitis

C virus (HCV) infection is responsible for graft loss and patient mortality.

Although the contribution of the immune system to fibrosis recurrence is

anticipated, systematic studies evaluating immune parameters as predictive

markers of allograft fibrosis are lacking. The infiltration of immune cells into

the graft is governed by chemokines. Here we assessed the predictive value of

serum levels of chemokines [chemokine (C-X-C motif) ligand 9 (CXCL9), CXCL10,

CXCL11, and chemokine (C-C motif) ligand 2 (CCL2)] with respect to fibrosis

recurrence after LT in 90 HCV-infected organ recipients. Chemokines were

determined within the first and third years after LT and were correlated with

histological fibrosis progression in protocol biopsy samples at 1, 3, 5, and 7

years (median follow-up = 3 years). The association of chemokines with fibrosis

progression was assessed by univariate and multivariate analyses and by

regression analysis. The results for the analyzed chemokines showed that CXCL10

levels in the first year after LT were strongly associated with early fibrosis

recurrence (P = 0.005) independently of risk confounders (including the donor

age, HCV viral load, HCV genotype, acute rejection, and inflammatory activity).

As assessed by regression analysis, a CXCL10 serum level ˜ 140 pg/mL was

significantly predictive of the absence of F2 fibrosis (P = 0.001), whereas a

level ˜ 220 pg/mL early after LT predicted the absence of F3 fibrosis during

follow-up (P = 0.035). Conclusion: CXCL10 is an independent biomarker of the

recurrence of significant fibrosis after LT for HCV infection. These results

might guide patients' care after transplantation and help us to select optimal

candidates for antiviral therapy post-LT. (HEPATOLOGY 2011;).

PMID: 21225643 [PubMed - as supplied by publisher]

[Guest guest]

Hepatology. 2010 Dec 6. [Epub ahead of print]

Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver

transplantation for hepatitis C infection.

Berres ML, Trautwein C, Schmeding M, Eurich D, Tacke F, Bahra M, Neuhaus P,

Neumann UP, Wasmuth HE.

Medical Department III, University Hospital Aachen, Aachen, Germany.

Abstract

The recurrence of liver fibrosis after liver transplantation (LT) for hepatitis

C virus (HCV) infection is responsible for graft loss and patient mortality.

Although the contribution of the immune system to fibrosis recurrence is

anticipated, systematic studies evaluating immune parameters as predictive

markers of allograft fibrosis are lacking. The infiltration of immune cells into

the graft is governed by chemokines. Here we assessed the predictive value of

serum levels of chemokines [chemokine (C-X-C motif) ligand 9 (CXCL9), CXCL10,

CXCL11, and chemokine (C-C motif) ligand 2 (CCL2)] with respect to fibrosis

recurrence after LT in 90 HCV-infected organ recipients. Chemokines were

determined within the first and third years after LT and were correlated with

histological fibrosis progression in protocol biopsy samples at 1, 3, 5, and 7

years (median follow-up = 3 years). The association of chemokines with fibrosis

progression was assessed by univariate and multivariate analyses and by

regression analysis. The results for the analyzed chemokines showed that CXCL10

levels in the first year after LT were strongly associated with early fibrosis

recurrence (P = 0.005) independently of risk confounders (including the donor

age, HCV viral load, HCV genotype, acute rejection, and inflammatory activity).

As assessed by regression analysis, a CXCL10 serum level ˜ 140 pg/mL was

significantly predictive of the absence of F2 fibrosis (P = 0.001), whereas a

level ˜ 220 pg/mL early after LT predicted the absence of F3 fibrosis during

follow-up (P = 0.035). Conclusion: CXCL10 is an independent biomarker of the

recurrence of significant fibrosis after LT for HCV infection. These results

might guide patients' care after transplantation and help us to select optimal

candidates for antiviral therapy post-LT. (HEPATOLOGY 2011;).

PMID: 21225643 [PubMed - as supplied by publisher]

[Guest guest]

Hepatology. 2010 Dec 6. [Epub ahead of print]

Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver

transplantation for hepatitis C infection.

Berres ML, Trautwein C, Schmeding M, Eurich D, Tacke F, Bahra M, Neuhaus P,

Neumann UP, Wasmuth HE.

Medical Department III, University Hospital Aachen, Aachen, Germany.

Abstract

The recurrence of liver fibrosis after liver transplantation (LT) for hepatitis

C virus (HCV) infection is responsible for graft loss and patient mortality.

Although the contribution of the immune system to fibrosis recurrence is

anticipated, systematic studies evaluating immune parameters as predictive

markers of allograft fibrosis are lacking. The infiltration of immune cells into

the graft is governed by chemokines. Here we assessed the predictive value of

serum levels of chemokines [chemokine (C-X-C motif) ligand 9 (CXCL9), CXCL10,

CXCL11, and chemokine (C-C motif) ligand 2 (CCL2)] with respect to fibrosis

recurrence after LT in 90 HCV-infected organ recipients. Chemokines were

determined within the first and third years after LT and were correlated with

histological fibrosis progression in protocol biopsy samples at 1, 3, 5, and 7

years (median follow-up = 3 years). The association of chemokines with fibrosis

progression was assessed by univariate and multivariate analyses and by

regression analysis. The results for the analyzed chemokines showed that CXCL10

levels in the first year after LT were strongly associated with early fibrosis

recurrence (P = 0.005) independently of risk confounders (including the donor

age, HCV viral load, HCV genotype, acute rejection, and inflammatory activity).

As assessed by regression analysis, a CXCL10 serum level ˜ 140 pg/mL was

significantly predictive of the absence of F2 fibrosis (P = 0.001), whereas a

level ˜ 220 pg/mL early after LT predicted the absence of F3 fibrosis during

follow-up (P = 0.035). Conclusion: CXCL10 is an independent biomarker of the

recurrence of significant fibrosis after LT for HCV infection. These results

might guide patients' care after transplantation and help us to select optimal

candidates for antiviral therapy post-LT. (HEPATOLOGY 2011;).

PMID: 21225643 [PubMed - as supplied by publisher]